FDA Approves Unknown Drug — GRAVITI PHARMS
Gravi Pharma announced that its generic drug has received FDA approval, a development expected to facilitate market entry and potentially generate revenue through competitive prici…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Gravi Pharma announced that its generic drug has received FDA approval, a development expected to facilitate market entry and potentially generate revenue through competitive prici…
Strides Pharma Intl announced the approval of a generic drug application in January 2006. This early-stage development marked a significant step for the company in establishing its…
# FDA Approves SOLA Pharmaceuticals' Generic Cabergoline The FDA has approved SOLA Pharmaceuticals' abbreviated new drug application for generic cabergoline oral tablets, potentia…
SUN PHARM INDUSTRIES received final FDA approval on December 21 for ANDA077124, signaling a potential generic opportunity in the previously undetermined market segment. The company…
# FDA Approves Torrent Pharmaceuticals' Generic Carbamazepine Torrent Pharmaceuticals Limited has received FDA approval for its generic carbamazepine oral formulation, expanding t…
Epic Pharma LLC announced the approval of its Abbreviated New Drug Application (ANDA) for generic drug **[Substance]** on October 27, 2005. This clearance positions Epic Pharma to …
# FDA Approves Generic Drug Application for Barr Pharmaceuticals Barr Pharmaceuticals received FDA approval for ANDA077083 on September 13, 2005, expanding its generic drug portfo…
Viona Pharmaceuticals Inc. has secured an approval for its DMF waiver on the generic label for metformin hydrochloride, opening the door to significant market traction as producers…
# FDA Approves Watson Labs Generic Drug Application Watson Labs received FDA approval for abbreviated new drug application ANDA076417 on April 18, 2005, expanding its generic phar…
E.R. Squibb & Sons, L.L.C. received FDA approval for Baraclude (entecavir) oral tablets in March 2005, positioning it as a potent therapeutic option for the chronic management of h…
E.R. Squibb & Sons, L.L.C. received FDA approval on March 29, 2005, for BARACLUDE (entecavir), an oral antiviral indicated for the treatment of chronic hepatitis B, launching the d…
Mylan Pharmaceuticals Inc. received FDA approval for its Abbreviated New Drug Application for transdermal fentanyl, authorizing the launch of a generic patch. This approval is expe…
Uronova Pharmaceuticals’ approval of its subcutaneous leuprolide acetate injection introduces new competition in the hormone therapy market, providing the company with a scalable r…
Sandoz received FDA approval on December 14, 2004, for its Abbreviated New Drug Application (ANDA076223), signaling a significant move downstream in the pharmaceutical value chain …
Sandoz has secured FDA approval for Abbreviated New Drug Application (ANDA) ANDA076873 on December 14, 2004, which will allow the company to immediately enter the market with a gen…
APOTEX has received approval from the US Food and Drug Administration for ANDA076706, a move that grants the company entry into the established market for this specific medication.…
Hikma Pharmaceuticals USA Inc. has announced the initiation of 180-day generic exclusivity for lithium carbonate oral tablets, replacing the Teva branded product. This move is expe…
Teva Pharmaceutical has announced the U.S. Food and Drug Administration's approval of an Abbreviated New Drug Application, potentially unlocking significant sales opportunities by …
# FDA Approves Hikma Pharmaceuticals' Intravenous Allopurinol Sodium Formulation Hikma Pharmaceuticals USA Inc. received FDA approval for allopurinol sodium for intravenous admini…
Impax Labs announced the July 30, 2004 approval of an Abbreviated New Drug Application (ANDA 076249) from the FDA, marking a significant milestone for its generic portfolio. This s…